Drugs / NPH/Regular 70/30 mix
last change Apr 2013 re-read 2 minutes ago

NPH/Regular 70/30 mix

Protein / enzyme biologic

Developed for
type 2 diabetes mellitus

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00821795 Comparator Mar 2009 → Apr 2013 type 2 diabetes mellitus Dennis G. Karounos, M.D. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NPH/Regular 70/30 mix ClinicalTrials.gov intervention name — accepted as the source's own label NCT00821795
Modality Protein / enzyme biologic “transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness” NCT00821795
Route Subcutaneous “injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration” NCT00821795